SoCalBio Networking Forums
December 18, 2008
According to the World Research Group, intangible assets comprise 70% or more of corporate asset value today. Nowhere is this truer than in the case of high-end device and certainly biotech companies. But many often fail to properly manage their IP and miss tremendous opportunities to capture revenues and recognize the value of their intangibles. Furthermore, many executives think that monetizing IP is a no-brainer and fail to take the necessary steps to derive most value out of it.
This forum seeks to address the above issues and provide some guidance to device and biotech firms about the best strategies to maximize IP valuation, particularly in the current uncertain economic environment.
Karen Gibbs and Amanda Paracuellos are panelists at this forum. They are speaking on the topic "Making Every Innovation Count: Monetizing IP Assets."